PSUSA/00010374/202401
Submitted by Anonymous (not verified) on 28 October 2024 - 9:50
PSUSA/00010374/202401
Orphan designation: Heterologous human adult liver-derived progenitor cells Treatment of argininosuccinic aciduria, 17/07/2013 Positive
Submitted by Anonymous (not verified) on 28 October 2024 - 8:00
Orphan designation: Heterologous human adult liver-derived progenitor cells Treatment of argininosuccinic aciduria, 17/07/2013 Positive
Orphan designation: Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4 Treatment of ovarian cancer, 19/03/2015 Positive
Submitted by Anonymous (not verified) on 28 October 2024 - 8:00
Orphan designation: Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4 Treatment of ovarian cancer, 19/03/2015 Positive
Orphan designation: Heterologous human adult liver-derived progenitor cells Treatment of ornithine-translocase deficiency, 17/07/2013 Positive
Submitted by Anonymous (not verified) on 28 October 2024 - 7:30
Orphan designation: Heterologous human adult liver-derived progenitor cells Treatment of ornithine-translocase deficiency, 17/07/2013 Positive
PSUSA/00010705/202401
Submitted by Anonymous (not verified) on 25 October 2024 - 14:52
PSUSA/00010705/202401
PSUSA/00000170/202401
Submitted by Anonymous (not verified) on 25 October 2024 - 14:50
PSUSA/00000170/202401
Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 25 October 2024 - 14:15
Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Date of authorisation: 14/01/2016, Revision: 19, Status: Authorised
Patient engagement in oncology
Submitted by Anonymous (not verified) on 25 October 2024 - 13:08
Patient engagement in oncology
Human medicines European public assessment report (EPAR): Oxervate, cenegermin, Date of authorisation: 06/07/2017, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 25 October 2024 - 11:46
Human medicines European public assessment report (EPAR): Oxervate, cenegermin, Date of authorisation: 06/07/2017, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 25 October 2024 - 11:19
Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 14, Status: Authorised